Shots:
- UroGen Pharma has reported P-III (ENVISION) trial data of Zusduri (mitomycin; QW, intravesical) as a chemoablative therapy for adults (n=240) with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
- Trial showed a 24mos. DoR of 72.2% (Kaplan-Meier) in pts with CR at 3mos., with a mFU of 23.7mos. after 3mos. CR; the mDoR was not reached
- Zusduri utilizes UroGen’s RTGel sustained-release hydrogel technology to deliver mitomycin directly into the bladder via catheter in an outpatient setting, allowing non-surgical tumor treatment
Ref: UroGen| Image: UroGen | Press Release
Related News:- UroGen Pharma Receives the US FDA’s Approval for Zusduri to Treat LG-IR-NMIBC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
